UNSPSC 51343307: Rociclovir

This classification denotes a purine antagonist and antiviral agent, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 6DF29U51Y7. European Medicines Agency schedules Rociclovir in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10351MIG. Rociclovir generally arises in the molecular formula C15H25N5O3. The term ROCICLOVIR is an International Non-Proprietary Name or INN. ROCICLOVIR is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix.

Most nations schedule rociclovir under HS 29335995 and SITC 51576. As of Q4 2014, ROCICLOVIR remains the US FDA Preferred Term for this commodity. Rociclovir bears US NLM identifiers UMLS ID C0643822 and NCI Concept Code C73204. SMILES: O(C(COC(C)C)COC(C)C)CN1C2NC(NCC2NC1)N.

UNSPSC 51343307 Rociclovir, a Commodity code, nominally addresses a specific antiviral pharmaceutical; however, recent state and local opportunities tagged under this code show minimal activity directly related to rociclovir and instead reflect broader pharmaceutical and medical supply procurement across health agencies and emergency responders. The work being solicited ranges from direct-to-manufacturer prescription programs and generic multi-source pharmaceuticals to naloxone and emergency medical supplies for fire and rescue divisions. Issuing bodies include state health and human services commissions, county health departments, municipal fire departments, and cooperative purchasing alliances spanning multiple states. The mix reflects both routine consumable replenishment and exploratory market-intelligence activities that inform larger pharmaceutical contracting strategies.

Recent activity appears concentrated in Florida, Texas, and Minnesota. The Texas Health and Human Services Commission issued an RFI (HHS0017013, posted April 3, 2026) soliciting vendor capabilities for a Therapeutic Pharmacy Initiative Direct-to-Manufacturer Prescriptions program—a market-research mechanism preceding formal RFP issuance. Seminole County, Florida released an IFB (IFB60459723LAS, due July 26, 2023) for 1,900 units of naloxone and 800 safe drug deactivation systems annually, with quarterly deliveries to the county health building. The City of Tampa released an ITB (26P00145, due March 13, 2026) for medical and first aid supplies—169 line items for the fire department rescue division, with an estimated contract value of $700,000.00 and a Small Local Business Enterprise set-aside with a 5 percent bid discount. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) issued an RFP (S1070000015802, due March 26, 2026) for generic multi-source pharmaceuticals and OTC products distributed across state and local facilities in Minnesota and Oregon, requiring vendors to supply through three authorized wholesalers and comply with cGMP and Drug Supply Chain Security Act certification.